England: CSL Undeterred By Draft NICE Rejection Of Its £2.6m Hemophilia B Gene Therapy

CSL Behring said it remains confident that a market access agreement for its hemophilia B gene therapy Hemgenix can be reached after England’s HTA body NICE rejected the product because of uncertainties over its long-term benefit and cost-effectiveness.